

AD _____

Award Number: W81XWH-08-1-0416

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk

PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

CONTRACTING ORGANIZATION: Health Research Inc
Buffalo, NY 14263

REPORT DATE: August 2009

TYPE OF REPORT: Annual report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

× Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-08-2009		2. REPORT TYPE Annual report		3. DATES COVERED (From - To) 1 AUG 2008-31 JUL 2009	
4. TITLE AND SUBTITLE Oxidative stress, DNA repair and prostate cancer risk				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-08-1-0416	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Hua Zhao, Ph.D. Email: hua.zhao@roswellpark.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Health Research Inc Buffalo, NY 14263				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research And Material Command Fort Detrick, Maryland, 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Oxidative stress, which results from an imbalance between ROS and antioxidant capacities, can cause a wide range of direct or indirect DNA damage. There are extensive DNA repair systems that can correct DNA damage caused by ROS before cell replication and mutation fixation. Although oxidative stress appears to be important in the etiology of prostate cancer, so far there is no study to comprehensively investigate the association between DRC of oxidative DNA damage as a phenotype and prostate cancer risk. We hypothesize that DRC of oxidative DNA damage as a phenotype may modify prostate cancer risk. So far, the study has recruited 156 cases and 132 controls. The proposed molecular analysis has begun for all three specific aims.					
15. SUBJECT TERMS microRNA ovarian cancer					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 5	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT UU	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusion.....	5

Introduction

Many of the known and suspected risk factors for prostate cancer are associated with elevated levels of ROS (advancing age, inflammation, androgen, high-fat diet), or decreased antioxidant capabilities (fruit and vegetable consumption, specific dietary antioxidants, such as selenium, vitamin E and carotenoids). Oxidative stress, which results from an imbalance between ROS and antioxidant capacities, can cause a wide range of direct or indirect DNA damage. There are extensive DNA repair systems that can correct DNA damage caused by ROS before cell replication and mutation fixation. For instance, ROS-caused base damages and single strand breaks are mainly repaired by BER and NER; DNA adducts caused by ROS-induced lipid peroxidation are repaired by NER; and ROS caused-DNA double strand breaks are repaired by HRR and NHEJ. However, DRC is substantially variable among individuals in the population, and suboptimal DRC of oxidative DNA damage might increase genomic instability and hence, increase risk of cancer. Although oxidative stress appears to be important in the etiology of prostate cancer, so far there is no study to comprehensively investigate the association between DRC of oxidative DNA damage as a phenotype and prostate cancer risk.

Body

Study subject recruitment: At the end of September of 2009, we have recruited 156 men diagnosed with prostate cancer as cases and 132 healthy men as controls. Both cases and controls were recruited through DataBank BioRepository (BDDR) of Roswell Park Cancer Institute (RPCI). On average, we have around 15 cases and 15 controls per month. We don't expect any significant delay to recruit 300 cases and 300 controls.

Specific aim 1: we will measure levels of 8-OH-dG after exposure to H_2O_2 in PBLs in 300 men with prostate cancer and 300 healthy controls, using ELISA based mutagen sensitivity assay. Our hypothesis is that cases will exhibit higher levels of 8-OH-dG after exposure to H_2O_2 (reflecting lower BER activity) compared with healthy controls. So far, the proposed 8-OH-dG analysis has been carried out in 98 prostate cancer cases and 87 healthy controls. The mean levels of 8-OH-dG were significantly higher in cases than in controls (4.52 vs. 3.11, $P < 0.01$). In further stratified analysis, using median levels of 8-OH-dG in controls as the cutoff point, we found higher levels of 8-OH-dG was associated with 1.45-fold increased prostate cancer risk (OR= 1.45, 95% CI: 1.04 to 2.35).

Specific aim 2: we will assess levels of DRC of DNA adducts induced by 4-HNE in PBLs in 300 prostate cancer cases and 300 healthy controls, using plasmid based modified HCR assay. 4-HNE is a major product of endogenous lipid peroxidation. 4-HNE caused DNA adducts is mainly repaired by NER. Our hypothesis is that cases will exhibit lower levels of NER of 4-HNE caused DNA adducts compared with healthy controls. So far, the proposed 4-HNE based host cell reactivation (HCR) assay has been carried out in 75 prostate cancer cases and 77 healthy controls. The mean levels of 4-HNE based HCR were marginally lower in cases than in controls (6.7% vs. 8.6%, $P = 0.052$). In further stratified analysis, using median levels of 4-HNE based in controls

as the cutoff point, we found lower levels of 4-HNE based was not associated with the prostate cancer risk (OR= 1.21, 95% CI: 0.75 to 1.89). Because of the small sample size, we have to be very cautious to interpret the results.

Specific aim 3: we will assess levels of HHR and NHEJ of double strand breaks in PBLs in 300 men with prostate cancer and 300 healthy controls, using plasmid based modified HCR assays. Our hypothesis is that cases will exhibit lower levels of HR and NHEJ compared with healthy controls. For HR assay, the assay has been carried out in 54 prostate cancer cases and 47 healthy controls. The mean levels of HR activity were lower in cases than in controls (10.5% vs. 12.4%, $P=0.34$), but the difference didn't reach statistically significant. For NHEJ assay, the assay has been carried out in 54 prostate cancer cases and 47 healthy controls. The mean levels of HR activity were lower in cases than in controls (7.9% vs. 8.9, $P=0.44$), but the difference didn't reach statistically significant.

Overall, we expect to complete the proposed analyses on time. No major delay is forecasted.

Key Research Accomplishments

1. At the end of September of 2009, we have recruited 156 men diagnosed with prostate cancer as cases and 132 healthy men as controls. We don't expect any delay in the study subject recruitment.
2. The proposed molecular analyses in specific aims 1-3 have run well. We expect to complete the proposed analyses on time.
3. We have obtained questionnaire data from 156 patients and 132 controls.
4. In training, Dr. Mohler (the mentor) has regularly consulted the project. Dr. Zhao has also involved in Dr. Mohler's other research project.

Reportable outcomes

Because the study is still ongoing, at this point, we don't have any manuscript in preparation. But, we expect to begin to prepare two manuscripts pretty soon.

Conclusion

The study has run smoothly so far. We don't expect any delay.